التصنيف: anti-diabetic.combined (sglt2) inhibitor with (dpp-4) inhibitor المادة الفعالة:empagliflozin+linagliptin
indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments 10 mg/5 mg po qday in morning taken with or without food dose may be increased to 25
